ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

IFM launches STING inhibitor company

by Ryan Cross
February 16, 2019 | APPEARED IN VOLUME 97, ISSUE 7

 

Boston-based IFM Therapeutics has launched a new subsidiary called IFM Due to develop small-molecule drugs for autoimmune and inflammatory diseases. IFM previously developed activators of a protein called STING—stimulator of interferon genes—which it sold to Bristol-Myers Squibb as part of a 2017 deal worth $300 million. Activating STING is a promising strategy for boosting cancer immunotherapies. Now IFM Due plans to develop inhibitors of STING, which is overactive in some autoimmune diseases.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment